Novo Nordisk’s Oral GLP-1 Offensive Meets a Wall Street Reality Check
Novo Nordisk faces revenue squeeze as oral Wegovy prescriptions plateau at starter doses, Eli Lilly enters the pill-based…
Novo Nordisk’s Oral GLP-1 Assault Begins as Earnings Cloud Hovers Over the Stock
Novo Nordisk rolls out oral semaglutide for diabetes and weight loss as Q1 earnings loom, with stock down…
Novo Nordisk Puts Oral Ozempic on Pharmacy Shelves Just Days Before a Make-or-Break Earnings Report
Novo Nordisk rolls out oral semaglutide as Ozempic in US pharmacies, facing revenue decline, pricing pressure, and fierce…
FDA Crackdown and Oral Ozempic Launch Set Stage for Earnings
Novo Nordisk enters a pivotal week with an FDA shortage-list victory, oral Ozempic rollout, and partnerships to capture…
Oral Ozempic Hits Pharmacies as Earnings Test Investor Patience
Novo Nordisk launches oral Ozempic in the US amid Q1 earnings decline, Eli Lilly competition, and patent pressures.…
Novo Nordisk’s Oral Ozempic Arrives as GLP-1 Data Opens New Frontier
Novo Nordisk enters a critical week with US launch of improved oral Ozempic, Lancet study showing semaglutide cuts…
Oral Ozempic Arrives as Q1 Results Loom
Novo Nordisk launches oral Ozempic in US pharmacies, faces Q1 earnings test amid margin concerns, and prepares obesity…
FDA Curbs Copycats as Oral Ozempic Hits 70,000 Pharmacies
Novo Nordisk gains 6% as FDA targets cheap semaglutide copies and launches first oral GLP-1 tablet in the…
Novo Nordisk’s Oral Wegovy Pill Surges Past Eli Lilly, but Generics and Price Pressure Loom
Novo Nordisk’s oral Wegovy pill leads Eli Lilly’s Foundayo 2-to-1 in US prescriptions, but faces generic competition in…
Novo Nordisk’s Oral Pill Crushes Lilly’s Foundayo in Prescription Race, but a 50% Stock Rout Tel
Eli Lilly’s Foundayo trails Novo Nordisk’s oral Wegovy in weekly scripts; Novo faces stock slump but scores pediatric…
Novo Nordisk’s Oral Wegovy Pill Leaves Eli Lilly in the Dust as Pipeline Battles Loom
Novo Nordisk shares jump 6.4% as oral Wegovy prescriptions dwarf Eli Lilly’s rival, while pivotal CagriSema trial data…
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged…